Parkinson Prize 2020 Best Research Article Recipient: Thomas Foltynie Best Review Article Recipients: Heiko Braak & Kelly Del Tredici | Launch of the Parkinson Prize The Journal of Parkinson's Disease (JPD) is pleased to announce the launch of the Parkinson Prize, coinciding with the anniversary celebrations commemorating the first 10 volumes of the journal. In the future, every year the Associate Editors of the journal will select the best article from the previous year's volumes. As this is the first occasion, the award period will cover the first years of the journal and a prize will be awarded for the best research article and one for the best review article. The awardee(s) will receive a Parkinson Prize trophy and a cash prize of $1,000 in recognition of outstanding contribution to the advancement of Parkinson’s disease (PD) research. The Parkinson Prize is presented by JPD and IOS Press. Details of the winners of the Parkinson Prize 2020 are outlined below, along with the runners-up of each prize. The Editors-in-Chief Patrik Brundin, MD, PhD, and Bastiaan Bloem, MD, PhD, comment: "The entire Editorial Board is delighted to formally recognize these important contributions to the literature on Parkinson’s disease and is honored to have the opportunity to publish such significant work in the journal." | WINNING RESEARCH ARTICLE
We are pleased to announce the prize for the best research article is presented to the lead author Thomas Foltynie, MD, PhD. The paper – “Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease” (Foltynie, et al., J Parkinsons Dis, 4, 337–344, 2014) – is freely available to read, download, and share. Read more about the author here. IMPORTANCE OF THE WORK
The study adds confidence that the potential beneficial effects of exenatide for the treatment of PD may be related to more than transient symptomatic benefits. The trial participants who used exenatide for one year as part of the investigators’ first trial were reviewed a year after stopping exenatide, and their "off dopaminergic medication" video assessments remained improved compared to the participants who were randomly assigned to the control group. "We have learned that careful long-term follow-up can be hugely instructive and have embraced the long-term follow up strategy in the evaluation of exenatide in our current phase 3 trial. My co-investigators and I are very honored that the Journal of Parkinson's Disease has chosen to recognize this article in this way," commented Prof. Foltynie. | WINNING REVIEW ARTICLE
We are pleased to announce the prize for the best review article is presented to the authors Heiko Braak, MD, and Kelly Del Tredici, MD, PhD. The paper – “Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff” (Braak & Del Tredici, J Parkinsons Dis, 7, S71–S85, 2017) – is freely available to everyone to read, download, and share. Read more about the authors here. IMPORTANCE OF THE WORK
Prof. Braak and Dr. Del Tredici review the development and rationale for the six-stage staging model they proposed for brain pathology related to sporadic Parkinson's disease (Neurobiol Aging 2003) and ensuing controversies. This staging model continues to fuel discussions as well as new hypotheses and new experimental models pertaining to the pathogenesis and pathomechanisms of Parkinson's disease. "Neuropathological staging of protein misfolding disorders helps to provide insights into the regional distribution of pathology, its potential systemic spread or propagation along neuroanatomical connectivities, and the selective vulnerability of specific types of neuronal and non-neuronal cells, whereby the prion-like concept of the synucleinopathy and the theory of selective vulnerability in Parkinson's disease are by no means mutually exclusive," explained Prof. Braak and Dr. Del Tredici. "We would like to thank the Journal of Parkinson's Disease Editorial Board members for their recognition of our work." | Runners-Up RESEARCH ARTICLES: Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson's Disease in Rodents (2018), Polinski, et al., J Parkinsons Dis, Vol.8, 303–322 Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease (2012), Khoo, et al., J Parkinsons Dis, Vol.2, 321–331 Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease (2019), Whone, et al., J Parkinsons Dis, Vol.9, 301–313 Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies (2016), Pagan, et al., J Parkinsons Dis, Vol.6, 503–517 REVIEW ARTICLES: The Synaptic Function of α-Synuclein (2015), Burré, J Parkinsons Dis, Vol.5, 699–713 The Emerging Evidence of the Parkinson Pandemic (2018), Dorsey, et al., J Parkinsons Dis, Vol.8, S3–S8 The Role of Innate and Adaptive Immunity in Parkinson's Disease (2013), Kannarkat, et al., J Parkinsons Dis, Vol.3, 493–514 The Role of Oxidative Stress in Parkinson's Disease (2013), Dias, et al., J Parkinsons Dis, Vol.3, 461–491 JPD is proud to host such high-quality work, and acknowledges the excellent contributions by these authors and all those who were in the running. | Help Spread the News of the Parkinson Prize 2020 If you know any colleagues and fellow researchers who are not signed up to receive the JPD newsletter, we invite you to share this mailing with them by clicking the link below. We have also promoted the Parkinson Prize 2020 announcement on the JPD social media accounts. You can find the tweet here and the Facebook post here. Feel free to share. Be part of the discussion! | You are receiving this mailing as you are signed up to receive news from JPD.
You can unsubscibe or alter your preferences at any time by clicking the links below. | |
